Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US6080910

Title:Transgenic knockout animals lacking IgG3
Inventors:Schreiber, John R.; Gates Mills, OH, USA
Greenspan, Neil S.; Shaker Height, OH, USA
Threadgill, Deborah S.; Nashville, TN, USA
Magnuson, Terry; Cleveland Heights, OH, USA
Summary:This invention describes new transgenic animals lacking IgG3, and uses thereof. Specifically, disclosed is a transgenic mouse comprising a genome with a homozygous disruption of an immunoglobulin gene, wherein the mouse expresses a reduced level of IgG3 relative to a corresponding wild-type mouse, and where the transgenic mouse further expresses wild-type level of an antibody selected from the group consisting of IgM and IgG2b. The antibody subtype is selectively inactivated via the disruption through homologous recombination of a nucleic acid sequence which encodes a constant region in the antibody subtype. Further provided are methods for using these transgenic animals for screening candidate therapeutic compounds, such as for activity against bacterial infection, and for producing monoclonal antibodies which contain reduced levels of IgG3.
Abstract:The present invention provides non-human transgenic animals in which an antibody subtype is selectively inactivated such that the transgenic animals express a reduced level of IgG3 relative to the levels expressed by the corresponding wild-type animal. Selective inactivation is achieved by the disruption through homologous recombination of the a nucleic acid sequence which encodes a constant region in the antibody subtype. The present invention provides transgenic animals which contain a disrupted C.gamma.3 gene. These transgenic animals retain the ability to express other antibody isotypes and subtypes. The present invention further provides methods for using these transgenic animals for screening candidate therapeutic compounds and for producing monoclonal antibodies which contain reduced levels of IgG3.
US Patent Website:Click Here for Full Text of Patent
Title Number:US6080910
Application Number:US1997000803120
Date Filed:20/02/1997
Date Published:27/06/2000
Assignee:Case Western Reserve University, Cleveland, OH, USA


 
Copyright © 2007 The Institute for Cellular Medicine  8/4/2020